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Obesity represents a significant health burden and the World Health Organisation 
recognises the importance of preventing weight gain and subsequent development of 
obesity among adults who are within the healthy weight range. Women of reproductive 
age have demonstrated high rates of weight gain during pregnancy placing them at risk 
of becoming overweight or obese. We will evaluate the effects of dietary and physical 
activity advice on maternal, fetal and infant health outcomes, among pregnant women 
of normal body mass index (BMI). 
METHODS AND ANALYSIS 
We will conduct a randomised controlled trial, consenting and randomising women 
with a live singleton pregnancy between 10+0-20+0 weeks, and BMI 18.5-24.9kg/m2 at 
first antenatal visit, from a tertiary maternity hospital. Women randomised to the 
Lifestyle Advice Group will receive 3 face-to-face sessions (2 with a research dietitian 
and 1 with a trained research assistant), and 3 telephone calls over pregnancy, in which 
they will be provided with dietary and lifestyle advice, and encouraged to make change 
utilising a SMART goals approach. Women randomised to the Standard Care Group 
will receive routine antenatal care. The primary outcome is infant birth weight >4kg. 
Secondary outcomes will include adverse infant and maternal outcomes, maternal 
weight change, maternal diet and physical activity changes, maternal quality of life and 
emotional wellbeing, fetal growth and costs of healthcare. We will recruit 624 women 
to detect a reduction from 8.72% to 3.87% (alpha 0.05 (two-tailed); power 70%) in 
infants with birth weight >4kg. Analyses will be intention to treat with estimates 
reported as relative risks and 95% confidence intervals.  
ETHICS AND DISSEMINATION 
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Ethical approval has been obtained from the Women’s and Children’s Hospital ethics 
committee. Findings will be disseminated widely via journal publication and 
conference presentation(s) and participants informed of results. 
TRIAL REGISTRATION NUMBER ACTRN 12614000583640 
 
STRENGTHS & LIMITATIONS 
 Robust evaluation of the effects of a dietary and lifestyle intervention during 
pregnancy for women of normal BMI. 
 Prospectively measured and calculated height, weight and BMI at the time of 
the first antenatal booking visit. 





World-wide, more than 1.9 billion adults, and 41 million children under the age of 5 
years are overweight or obese.1 Obesity represents a significant healthcare burden, with 
the World Health Organisation recognising the importance of preventing weight gain 
among adults who are within the healthy weight range.2 Women of reproductive age 
have demonstrated high rates of gestational weight gain (GWG) during pregnancy, and 
post-partum weight retention (PPWR),3 and therefore represent an “at-risk” population. 
 
The Institute of Medicine (IoM) has reviewed the considerable observational literature 
which is available, recommending GWG between 11.5 and 16.0kg for pregnant women 
of normal body mass index (BMI), defined as BMI between 18.5 and 24.9kg/m2.4 
Weight gain in excess of these recommendations is well recognised as a significant risk 
factor for adverse maternal and infant outcomes during pregnancy and childbirth, even 
among women of normal BMI,5-8 and more than doubles a woman’s risk of postpartum 
weight retention.9 Indeed, more than 70% of women with a BMI retain more than 5kg 
weight up to 1 year after birth,10 11 contributing to an increase in inter-pregnancy BMI, 
an increased risk of adverse outcomes in a subsequent pregnancy, and longer-term risk 
of obesity.12-14 There is also increasing evidence that excessive GWG increases the 
chance of high infant birth weight, with both factors independently associated with an 
increased risk of child obesity.15-17 Specifically, the risk of early childhood obesity 
increases by a factor of 1.08 (95% CI 1.03-1.14) per kilogram of maternal weight 
gained above the recommendations.18 All of these factors combine to create a vicious 
cycle in which the intergenerational effects of obesity are perpetuated.19 
While there is extensive observational literature defining the pregnancy and childbirth 
complications associated with excessive GWG and postpartum weight retention for 
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women of normal BMI, there is limited information describing effective interventions. 
Our systematic review of the literature identified 12 RCTs of 2,713 pregnant women, 
who were recruited across all BMI categories.20 Of these trials, 8 specifically identified 
1,048 women to be of normal BMI, of which only 5 reported clinical outcomes for 
women of normal BMI (714 women).20 Women of normal BMI who received an 
antenatal intervention gained less weight (1.25kg; 95% CI -2.39 to -0.11) than those 
women receiving standard antenatal care, and were less likely to have weight gain 
above the IoM recommendations (RR 0.72; 95% CI 0.60 to 0.86; 5 studies, 714 
women).20 However, the effect on clinical pregnancy outcomes was less clear (2 
studies, 243 women), and only two studies reported post-partum weight retention at 8 
weeks and 6 months after birth.20 While there was a modest overall effect on GWG, 
effects on clinical pregnancy and birth outcomes have been poorly reported to date, and 
there is no information relating to longer-term effects on both maternal and child health. 
 
The aims of the OPTIMISE randomised trial are to evaluate the effects of dietary and 
physical activity advice on maternal, fetal and infant health outcomes, among pregnant 
women of normal BMI. 
 
METHODS AND ANALYSIS: 
Study Design: Randomised controlled trial. 
 
Inclusion Criteria: Women with a singleton, live gestation between 10+0-20+0 weeks 
who are of normal BMI (BMI 18.5 to 24.9kg/m2) at their first antenatal visit will be 
eligible to participate. 
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Exclusion Criteria: Women with a multiple pregnancy, or who have type 1 or 2 diabetes 
which was diagnosed prior to pregnancy will be excluded from participation. 
 
Trial Entry: Eligible women will be identified in the antenatal clinic of the Women’s 
and Children’s Hospital, given the trial information sheet and counselled by a 
researcher, before obtaining informed written consent. Randomisation will occur using 
the computer based randomisation service in the Discipline of Obstetrics and 
Gynaecology, The University of Adelaide. Recruitment commenced June 2014, and the 
study is ongoing. 
 
The randomisation schedule will use balanced variable blocks, and will be prepared by 
an investigator not involved with recruitment or clinical care. There will be 
stratification of women according to parity (0 versus 1 or more). Eligible women will 
be randomised to either the ‘Lifestyle Advice Group’ or the ‘Standard Care Group’. 
Blinding of participants is not possible given the nature of the intervention. Where 
possible, antenatal care-providers, outcome assessors and data analysts will be blinded 
to treatment allocation. 
 
Treatment Schedules: Women who are randomised to the Lifestyle Advice Group will 
receive 3 individual face-to-face sessions during pregnancy, with 2 provided by the 
dietitian shortly after trial entry and again at 28 weeks gestation, and one provided by 
a research assistant at 36 weeks gestation. Women will also receive 3 telephone calls 
from the research assistant at 20, 24, and 32 weeks gestation. The dietary advice 
provided will be individually tailored, consistent with current Australian dietary 
standards,21 and based on our experience with the LIMIT randomised trial.22 23 
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Recommendations and dietary targets will be individualised, taking into account each 
woman’s basal metabolic rate and activity levels.24 The dietary intervention will 
maintain a balance of carbohydrates, fat and protein, while specifically encouraging 
women to reduce their intake of energy dense and non-core foods high in refined 
carbohydrates and saturated fats, while increasing their intake of fibre, and to consume 
of two serves of fruit, five serves of vegetables, and three serves of dairy each day.21-23 
 
Tailoring of the intervention will be informed by stage theories of health decision 
making that propose that individuals progress through a series of cognitive phases when 
undertaking behavioural change.25 Initially, there will be a planning session with a 
research dietitian, in which women will be provided with written dietary and activity 
information, an individual diet and physical activity plan, recipe book and example 
menu plans. Women will be encouraged to set achievable goals for dietary and physical 
activity change, supported to make these lifestyle changes and to self-monitor their 
progress, using a SMART goals approach. Women will be encouraged to involve their 
partner or significant support person in these sessions. These principles will be 
reinforced at subsequent face-to-face visits with the dietitian and research assistant, and 
during the telephone contacts.22 23 
  
Women who are randomised to the Standard Care Group will receive their antenatal 
care according to their local hospital practice, which does not currently include 
information relating to dietary intake and physical activity during pregnancy.  
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Ongoing Follow-up of All Women in Both Treatment Groups:  
All women will be asked to complete a food frequency questionnaire, physical activity 
diary, and quality of life assessments at trial entry, 28 and 36 weeks gestation, and six 
months postpartum. Their weight will be recorded at trial entry, at 28 weeks gestation, 
and at 36 weeks gestation or nearest to birth. All women will be encouraged to attend 
for a research ultrasound at 28 and 36 weeks gestation that does not constitute routine 
clinical care to monitor fetal growth and wellbeing.  
 
After birth, information will be obtained relating to birth and infant outcomes from the 
case notes by the research assistant, who will remain blinded to the woman’s allocated 
treatment group.  
 
Study Endpoints:  
The primary trial outcome is the incidence of infants with birth weight >4 kg. 
 
The secondary study outcomes are 
1) Adverse outcomes for the infant including preterm birth (birth before 37 weeks 
gestation); mortality (either stillbirth (intrauterine fetal death after trial entry and prior 
to birth), or infant death (death of a live born infant prior to hospital discharge, and 
excluding lethal congenital anomalies)); infant birth weight; infant birth weight <2500 
grams; infant birth weight >4500 grams; large for gestational age defined as infant birth 
weight >90th percentile for gestational age and infant sex; small for gestational age 
defined as infant birth weight <10th percentile for gestational age and infant sex; 
hypoglycaemia requiring intravenous treatment; admission to neonatal intensive care 
unit, or special care baby unit; hyperbilirubinaemia requiring phototherapy; nerve 
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palsy; fracture; birth trauma; shoulder dystocia; corticosteroid use; respiratory distress 
syndrome (with moderate or severe respiratory disease defined as mean airway pressure 
>10cm H2O and/or inspired oxygen fraction (FiO2) >0.80 with ventilation);
26 discharge 
home on oxygen; patent ductus arteriosis; proven systemic infection requiring 
treatment; retinopathy of prematurity; necrotising enterocolitis; neonatal 
encephalopathy;27 seizures; length of stay; and infant exclusively breast fed at hospital 
discharge. 
 
2) Adverse outcomes for the woman including maternal hypertension and pre-
eclampsia (in accordance with recognised Australasian Society for the Study of 
Hypertension in Pregnancy criteria)28; maternal gestational diabetes; need for and 
length of antenatal hospital stay; antepartum haemorrhage requiring hospitalisation; 
preterm prelabour ruptured membranes; chorioamnionitis; need and reason for 
induction of labour; any antibiotic use during labour; caesarean section; postpartum 
haemorrhage (blood loss >600mL); perineal trauma; wound infection; endometritis; 
length of postnatal hospital stay; thromboembolic disease; maternal death. 
 
3) Maternal weight changes including total gestational weight gain; average weekly 
gestational gain; gestational weight gain below / within / above IoM recommendations;4 
maternal weight at 6, 12, and 18-24 months after birth to calculate postpartum weight 
retention; return to early pregnancy weight; and anthropometric assessment (skin-fold 
thickness, body circumferences, and bio-impedance to assess adiposity). 
 
4) Maternal changes in diet and physical activity as measured by questionnaires 
completed by the woman at trial entry, 28 and 36 weeks gestation, and 6, 12 and 18-24 
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months after birth (Harvard Semi-quantitative Food Frequency Questionnaire,29 30 and 
the Short Questionnaire to Assess Health-enhancing physical activity (SQUASH)31). 
 
5) Maternal quality of life and emotional wellbeing as measured by questionnaires 
completed by the woman at six months postpartum relating to quality of life (as 
measured using the SF12 Health Survey Questionnaire);32 preferences for treatment, 
satisfaction with care; anxiety (as measured by the Short Form Spielberger State Trait 
Inventory33) and depression (as measured by the Edinburgh Postnatal Depression 
Scale34). Women will be asked a series of questions about their satisfaction with the 
intervention, using items modified from a previous childbirth questionnaire.35  
 
6) Fetal growth and wellbeing at 28 and 36 weeks’ gestation assessed by ultrasound 
(fetal biometry, estimated weight, liquor volume, umbilical artery Doppler waveform, 
and adiposity).36  
 
7) Costs of health care: The primary measure of outcome for the economic analysis will 
be the cost per live birth. Resource use will include the provision of the dietary 
intervention and direct costs of health care (expected average clinic fees, the frequency 
and duration of GP and antenatal visits, as well as in-patient admissions), determined 
by hospital out-patient visits, in-patient admissions and published data sets including 
PBS, MBS and Australian Refined Diagnosis Related Groups (AR-DRG) cost weights. 
Mean costs and effectiveness between treatment groups will be compared and 
incremental cost effectiveness ratios (ICERs) and confidence intervals presented. For 
varying threshold values of cost effectiveness, acceptability curves will be presented as 
described previously.37 An assessment of the sensitivity of the results to variation in 
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measured resource use, effectiveness and/or unit costs will be undertaken using 
appropriate one-way and multi-way sensitivity analysis, as described previously.37  
 
Sample Size Estimation:  
The primary clinical endpoint is the incidence of infants born with birth weight >4kg, 
with an estimated incidence in women eligible for this trial of 8.72%.38 To detect a 
difference from 8.72% to 3.89% (alpha 0.05; power 70%), we will recruit a total of 624 
women. This sample size will be powered (70%) to detect the differences in secondary 
outcomes as detailed in table 1 below. 
Table 1: Estimated differences in secondary outcomes. 
Outcome Assumed Control Group % Intervention %  
GDM 3.4 0.6 
Hypertension/Pre-Eclampsia 4.6 1.3 
Induction of labour 26.8 18.5 
Caesarean Section 24.6 16.6 
Birth weight < 2.5kg 6.2 2.2 
 
Analysis and Reporting of Results:  
The initial analysis will examine baseline characteristics of all randomised women, as 
an indication of comparable treatment groups, and include maternal age, parity, race, 
height, weight, smoking history, past obstetric history, and previous gestational 
diabetes. Primary and secondary outcomes will be analysed on an “intention to treat” 
basis, according to treatment allocation at randomisation. Relative risks and 95% 
confidence intervals will be reported for the major outcomes, and the number needed 
to treat to benefit or harm calculated. Regression techniques will examine the influence 
of prognostic factors on the major outcomes.  
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As the lead investigator, JMD will have access to the data, and acts as guarantor to the 
final data set. The trial manager (ARD) and statistician (JL) will have access to the data, 
and the statistician (JL) will be responsible for the development of the statistical 
analysis plan, prior to the conduct of any statistical analyses. 
 
ETHICS AND DISSEMINATION: 
Data Management: 
All information obtained from this study will remain strictly confidential. While the 
results of the study will be published, no data will be presented to allow the 
identification of individual women. Data will be stored in a locked filing cabinet or on 
password protected computer file, and accessible only by the study team. 
 
We have previous experience recruiting women for lifestyle intervention trials in this 
setting 23 and will consider adding further sites as required.  Women who withdraw 
from ongoing participation after randomisation will be asked for consent to utilise the 
data already collected prior to withdrawal, including birth outcomes where possible. 
 
Following completion of the relevant statistical analyses, manuscripts will be prepared 
for publication, with subsequent presentation of results at relevant scientific and clinical 
meetings. Participants will be notified of the findings of the trial. The findings of this 
trial will contribute to the currently available literature regarding the effect of antenatal 
dietary and lifestyle interventions for women of normal BMI, and to the development 
of evidence based clinical practice guidelines. 
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Recruitment commenced in June 2014. We expect to have completed data collection 
and data cleaning by April 2018. The final results of the trial will be published in 
international peer-reviewed journals. 
 
Ethical Approval:  
Approval to conduct this study has been obtained from the research and ethics 
committee of the Women’ s and Children’ s Hospital (Adelaide, South Australia). 
 
A data and safety monitoring board (DSMB) will monitor efficacy (or futility) and 
adverse effects. Based on these considerations, the DSMB may recommend that the 
protocol be modified or that the OPTIMISE trial be terminated. The DSMB will consist 
of experts in relevant obstetrics, neonatology and research methodology. All adverse 
events involving women and infants enrolled in the trial will be reviewed by a 
multidisciplinary committee, who will be blinded to treatment allocation, in order to 
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